Show simple item record

dc.contributor.authorOsuji, Nen_US
dc.contributor.authorMatutes, Een_US
dc.contributor.authorTjonnfjord, Gen_US
dc.contributor.authorGrech, Hen_US
dc.contributor.authorDel Giudice, Ien_US
dc.contributor.authorWotherspoon, Aen_US
dc.contributor.authorSwansbury, JGen_US
dc.contributor.authorCatovsky, Den_US
dc.date.accessioned2018-09-03T13:11:22Z
dc.date.issued2006-08-01en_US
dc.identifier3en_US
dc.identifier.citationCANCER, 2006, 107 pp. 570 - 578en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2520
dc.identifier.eissn1097-0142en_US
dc.identifier.doi10.1002/cncr.22032en_US
dc.description.abstractBACKGROUND. To the authors’ knowledge, there is no standard treatment for patients with T-cell large granular lymphocyte (LGL) leukemia. Available data are limited by patient numbers and coexisting pathologies. METHODS. The authors report on the use of immunosuppressants (cyclosporin A [CSA] and low-dose oral methotrexate [MTX] given continuously) and cytotoxic agents in the treatment of 29 patients with T-cell LGL leukemia age over the past 20 years. RESULTS. The overall response rate (ORR) to MTX (n = 8 patients) was 85.7% (complete hematologic response [CHR] rate, 14.3%; partial response [PR] rate, 71.4%) with dose-dependent responses observed and safe usage of doses > 10 mg/m(2) per week in 2 patients. The ORR to CSA (n = 23 patients). was 78.2% (CHR rate, 30.4%; PR rate, 47.8%). The median time to response for both agents was I month. Toxicity; although it was minor in most patients and was more common in the CSA group, included second malignancies in 5 patients. An ORR of 67% (all CHR) was attained with pentostatin (n = 4 patients); recurrences developed after a median of 4.6 years. Successful retreatment with pentostatin was possible but with increasing drug resistance. Cyclophosphamide induced CHR that lasted > 7 years with bone marrow clearance in 1 of 4 patients. Alemtuzumab induced a PR in 1 patient who had refractory disease. CONCLUSIONS. Both MTX and CSA were efficacious in the treatment of T-cell LGL leukemia but generally required long-term maintenance therapy. The authors highlight the risks of second malignancies and persistence of bone marrow disease. Although MTX and CSA were effective as first-line therapy, alemtuzumab and pentostatin merit further investigation, particularly for refractory disease.en_US
dc.format.extent570 - 578en_US
dc.titleT-cell large granular lymphocyte leukemia - A report on the treatment of 29 patients and a review of the literatureen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1002/cncr.22032en_US
rioxxterms.licenseref.startdate2006-08-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCANCERen_US
pubs.notesresearcherid-numbers: Del Giudice, Ilaria/K-6027-2016 orcid-numbers: Del Giudice, Ilaria/0000-0001-6864-9533 unique-id: ISI:000239157800017en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume107en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorMatutes, Estellaen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record